References

medalphabet

Медицинский алфавит

Medical alphabet

2078-56312949-2807

ООО «Альфмед»

10.33667/2078-5631-2019-2-14(389)-6-14

medalphabet-1314

Research Article

Статьи

Риск и возможности профилактики сердечно-сосудистых заболеваний у женщин в пери- и постменопаузе

Risk and possibilities of preventing cardiovascular diseases in women in peri- and postmenopause

Кузнецова

И. В.

Kuznetsova

I. V.

д. м. н., проф. кафедры акушерства и гинекологии № 1 лечебного факультета

г. Москва

Moscow

ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияFirst Moscow State Medical University n. a. I. M. SechenovRussian Federation

2019

30112019

214

Современная гинекология

614

2019

Кузнецова И.В.

Kuznetsova I.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-alphabet.com/jour/article/view/1314

Сердечно-сосудистая заболеваемость остается ведущей причиной смертности в мире как у мужчин, так и у женщин. Но программы профилактики сердечно-сосудистых заболеваний (ССЗ), позволившие существенно снизить частоту кардиоваскулярных осложнений среди мужчин, оказались неэффективными среди женской популяции. Отличия факторов риска ССЗ у разных полов, разная ответная реакция женского и мужского организма на однотипные лечебные воздействия побуждают, с одной стороны, к развитию гендерно ориентированной кардиологической практики и, с другой стороны, определяют необходимость включения гинекологов в разработку и осуществление мероприятий по снижению сердечно-сосудистой заболеваемости и смертности.

Cardiovascular morbidity remains the leading cause of death in the world, in both men and women. But the programs for the prevention of cardiovascular diseases (CVD), which significantly reduced the incidence of cardiovascular complications among men, proved to be ineffective among the female population. Differences in CVD risk factors in different sexes, different responses of the female and male organism to the same treatment effects induce, on the one hand, the development of gender-oriented cardiological practices and, on the other hand, determine the need to include gynecologists in the development and implementation of cardiovascular reduction measures vascular morbidity and mortality.

сердечно-сосудистые заболеванияартериальная гипертензиясахарный диабетожирениеменопаузальный метаболический синдромполовые стероидыменопаузаменопаузальная гормональная терапия

cardiovascular diseasesarterial hypertensiondiabetes mellitusobesitymenopausal metabolic syndromesex steroidsmenopausemenopausal hormone therapy

References1

Perk J., De BG, Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635–1701.

Towfighi A., Zheng L., Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009; 169: 1762e1766.

Swindell WR, Johnston A, Sun L, et al. Meta-Profiles of Gene Expression during Aging: Limited Similarities between Mouse and Human and an Unexpectedly Decreased Inflammatory Signature. PLoS ONE. 2012; 7(3): e33204.

Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011; 9: 120–138.

Сметник В. П., Ильина Л. М. Роль половых гормонов в развитии метаболических расстройств у женщин в пери- и ранней постменопаузе. Климактерий, 2009; 1: 8–13.

Zhang Y, Klein K, Sugathan A, et al. Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One. 2011; 6: e23506.

Villa A, Della Torre S, Stell A, Cook J, Brown M, Maggi A. Tetradian oscillation of estrogen receptor alpha is necessary to prevent liver lipid deposition. Proceed Nation Acad Sci USA. 2012; 109: 11806e11811.

Palmasano BT, Zhu BT, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein metabolism. Mol Metab. 2018; 15: 45–55.

Anagnostis P, Majeed A, Johnston DG, Godsland IF. Cardiovascular risk in women with type 2 diabetes mellitus and prediabetes: is it indeed higher than men? Eur J Endocrinol. 2014; 171: R 245–255.

Regensteiner JG, Golden S, Huebschmann AG, et al. Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American heart association. Circulation. 2015; 132: 2424e2447.

Saltevo J, Kautiainen H, Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend Med. 2009; 6: 463–470.

Kautzky-Willer A, Kamyar MR, Gerhat D, et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gend Med. 2010; 7: 571–583.

Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt). 2014; 23: 112–119.

Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. 2014; 383: 1973–1980.

Boggia J, Thijs L, Hansen TW, et al. Ambulatory blood pressure monitoring in 9357 subjects from 11 populations highlights missed opportunities for cardiovascular prevention in women. Hypertension. 2011; 57: 397–405.

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159–2219.

Fried SK, Lee MJ, Karastergiou K. Shaping fat distribution: new insights into the molecular determinants of depot- and sex-dependent adipose biology. Obesity (Silver Spring). 2015; 23: 1345e1352.

Leeners B, Geary N, Tobler PN, Asarian L. Ovarian hormones and obesity. Hum Reprod Update. 2017; 23: 300–321.

Stefanska A, Bergmann K, Sypniewska G. Metabolic syndrome and menopause: pathophysiology, clinical and diagnostic significance. Adv Clin Chem. 2015; 72: 1–75.

Bassuk SS, Manson JE. Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification. Clin Chem. 2014; 60:68–77.

Wild RA, Wu C, Curb JD, et al. Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women’s Health Initiative randomized clinical trials. Menopause. 2013; 20: 254–260.

Collins P, Webb CM, de Villiers TJ, Stevenson JC, Panay N, Baber RJ. Cardiovascular risk assessment in women — an update. Climacteric. 2016; 19: 329–336.

Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol. 2016; 23: 178–186.

Wilmot KA, O’Flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary heart disease mortality declines in the United States from 1979 through 2011: evidence for stagnation in young adults, especially women. Circulation. 2015; 132: 997e1002.

Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statisticsd2017 update: a report from the American Heart Association. Circulation. 2017; 137: e1ee458.

Gast GC, Pop VJ, Samsioe GN, et al. Vasomotor menopausal symptoms are associated with increased risk of coronary heart disease. Menopause 2011; 18: 146–151.

Thurston RC, El Khoudary SR, Sutton-Tyrrell K, et al. Vasomotor symptoms and insulin resistance in the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2012; 97: 3487–3494.

Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014; 34: 509–515.

Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Powell LH, Matthews KA. Hot flashes and carotid intima media thickness among midlife women. Menopause. 2011; 18: 352–358.

Tuomikoski P, Ebert P, Groop PH, et al. Effect of hot flushes on vascular function: a randomized controlled trial. Obstet Gynecol. 2009; 114: 777–785.

Hoikkala H, Haapalahti P, Viitasalo M, et al. Association between vasomotor hot flashes and heart rate variability in recently postmenopausal women. Menopause. 2010; 17: 315–320.

Buber J, Mathew J, Moss AJ, et al. Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2. Circulation. 2011; 123: 2784–2791.

Pavanello C, Mombelli G. Considering gender in prescribing statins: what do physicians need to know? Clin Lipidol. 2015; 10: 499e512.

Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: A meta-analysis. J Gen Intern Med. 2011; 26: 1336–1344.

Garcia M, Mulvagh SL, Noel Bairey Merz C, Buring JE, Manson JE. Cardiovascular Disease in Women: Clinical Perspectives. Circ Res. 2016; 118(8): 1273–1293.

Pagano G, Talamanca AA, Castello G, Cordero MD, et al. Oxidative stress and mitochondrial dysfunction across broad-ranging pathologies: toward mitochondria-targeted clinical strategiesю Oxid Med Cell Longev. 2014; 2014: 541230.

Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Ann Rev Med. 2009; 60: 39–54.

Romani A. M. Magnesium in health and disease. Met Ions Life Sci. 2013; 13: 49–79.

Heaney RP, Kopecky S, Maki KC, Hathcock J, MacKay D, Wallace TC. A Review of Calcium Supplements and Cardiovascular Disease Risk. Adv Nutr. 2012; 3(6): 763–771.

Ginde AA, Scragg R, Schwartz RS, Camargo CA. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all cause mortality in older U.S. adults. J Am Geriatr Soc. 2009; 57 (9): 1595–603.

Liu E, Meigs JB, Pittas AG et al. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139: 329–334.

Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, Franconi F, Gerdts E, Foryst-Ludwig A, Maas AH, Kautzky-Willer A, Knappe-Wegner D, Kintscher U, Ladwig KH, Schenck-Gustafsson K, Stangl V. Gender in cardiovascular diseases: Impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016; 37: 24–34.

James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (jnc 8). JAMA. 2014; 311: 507–520.

Manson JE, Bassuk SS. The menopause transition and postmenopausal hormone therapy. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jamison JL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. McGraw-Hill; 2011.

Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010; 95: S 1–S 66.

Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol. 2012; 120: 595–603.

Baber RJ, Panay N, Fenton A, and the IMS Writing Group. Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016: 19: 109–150.

Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310: 1353–1368.

Hodis H, Mack WJ, Henderson V, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016; 374: 1221–1231.

Clarkson TB, Melendez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 2013; 20(3): 342–353.

Hodis HN, Collins P, Mack WJ, Schierbeck LL. The window of opportunity for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15(3): 217–228.

Nudy M, Chichilli VM, Foy AJ. A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke. IJC Heart & Vasculature. 2019; 22: 123–131.

Reslan OM, Khalil RA. Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials. 2012; 7: 47–70.

Agarwal S, Alzahrani FA, Ahmed A. Hormone replacement therapy: would it be possible to replicate a functional ovary? Int J Mol Sci. 2018; 19: 3160.

Scarpin KM, Graham JD, Mote PA, Clarke CL. Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression. Nucl Recept Signal. 2009; 7: e009.

Clark MA, Harvey RA, Finkel R, Rey JA, Whalen K. Pharmacology. US: Lippincott Williams & Wilkins. 2011. p. 322.

Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013; 34: 171.

Nath A, Sitrukware R. Different cardiovascular effects of progestins according to structure and activity. Climacteric. 2009; 12(Suppl 1): 96–101.

Bińkowska M, Woroń J. Progestogens in menopausal hormone therapy. Prz Menopauzalny 2015; 14(2): 134–143.

Jameson JL, de Kretser DM, Marshall JC, De Groot LJ. Endocrinology Adult and Pediatric: Reproductive Endocrinology. Elsevier Health Sciences: Amsterdam, The Netherlands, 2013.

Foumier A, Dossus L, Mesrine S, Viller A, Boutron-Ruault MC, Ckavel-Chapelon F, Chabbert-Buffet N. Risks of endometrial cancer associated with different hormone replacement therapies in the E 3N cohort, 1992–2008. Am J Epidemiol. 2014; 180(5): 508–517.

Yifan J, Tian W. The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis. 2017; 16: 219.

Prior JC, Elliott TG, Norman E, Stajic V, Hitchcock CL. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One. 2014; 9: e84698.

Smith GI, Reeds DN, Okunade AL, Patterson BW, Mittendorfer B. Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. J Clin Endocrinol Metab. 2014; 99: E 1306–10.

Casanova G, Spritzer PM. Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial. Lipids Health Dis. 2012; 11: 133.

Hellgren M, Conard J, Norris L, Kluft C. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone. Maturitas 2009; 62: 287–293.

Stevenson JC, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. Maturitas 2013; 76: 10–21.

Паневина А. С., Сметнева Н. С., Василенко А. М., Шестакова М. В. Влияние менопаузальной гормональной терапии на содержание провоспалительных цитокинов и иммуноглобулинов при коморбидности сахарного диабета 2-го типа и хронической обструктивной болезни легких в период постменопаузы. Терапевтический Архив. 2018; 10: 79–83.

Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2010; 95(7 Suppl 1): s1–s66.

Bureau G, Olié V, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. 2010. Menopause; 17: 1122–1127.

Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism. Results from the E 3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30: 340–345.

Karim R, Stanczyk FZ, Hodis HN, Cushman M, Lobo RA, Hwang J, Mack WJ. Associations between Markers of Inflammation and Physiological and Pharmacological Levels of Circulating Sex Hormones in Postmenopausal Women. Menopause. 2010; 17(4): 785–790.

Sharma G, Mauvais-Jarvis, F, Prossnitz ER. Roles of G protein-coupled estrogen receptor GPER in metabolic regulation. J Steroid Biochem Mol Biol. 2018; 176: 31e37.

Quatresooz P, Pierard GE. Immunohistochemical clues at aging of the skin microvascular unit. J Cutan Pathol. 2009; 36(1): 39–43.

Kinoshita M, Yokote K, Arai H, et al, Committee for Epidemiology and Clinical Management of Atherosclerosis. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018; 25(9): 846–984.

Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009; 26: 1–9.

Lovre D, Lindsey SH, Mauvais-Jarvis F. Effect of menopausal hormone therapy on components of the metabolic syndrome. Ther Adv Cardiovasc Dis. 2017; 11(1): 33–43.

Nelson HD, Walker M, Zakher B, Mitchel J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U. S. Preventive Services Task Force Recommendations. Ann Intern Med. 2012; 157: 104–113.

Archer DF, Schmelter T, Schaefers M, Gerlinger C, Gude K. A randomized, double blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014; 21(3): 227–235.

Балан В. Е., Журавель А. С., Лопатина О. В., Орлова С. А. Эволюция менопаузальной гормонотерапии: от стандартных доз к ультранизким. Медицинский совет. 2016; (2): 74–78.

Сметник А. А. Менопаузальная гормонотерапия с дидрогестероном: аспекты эффективности и безопасности ультранизких доз. Медицинский совет. 2017; (2): 92–99.

Stevenson JC, Durand G, Kahler E, et al. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010; 67: 227–232.

The authors declare that there are no conflicts of interest present.